Novel Tool Identifies New Therapeutic Targets for Complex Diseases and Cancer

Researchers at The Rockefeller University have developed a new platform called PerturbFate that may identify new therapeutic targets for complex diseases, including cancer and neurodegeneration. The tool is designed to map how various genetic mutations reshape cells and identify shared regulatory targets, providing a potential strategy for treating conditions driven by a wide array of genetic causes.

Complex diseases often arise from genetic misfires involving hundreds of mutations across diverse pathways. Because these mutations span different functionalities—ranging from cell signaling to gene regulation—it has historically been difficult for scientists to connect a constellation of mutations to a specific disease outcome or to design a single therapy that can address them collectively.

Mapping Regulatory Nodes

PerturbFate addresses this challenge by systematically mapping how different disease-associated genetic variations reshape cells and identifying where those different paths converge. The platform allows researchers to observe these changes in real time by tracking RNA production and processing, as well as DNA accessibility, within single cells over time.

The goal of the platform is to identify regulatory nodes, which are common control points where diverse genetic perturbations funnel into the same harmful cell state. Rather than attempting to target every individual mutation, researchers can instead target these shared downstream signaling points.

We focus here on cancer drug resistance, but the paper really starts from a broader question: once you know that a disease is associated with hundreds of genes, how do you design one therapy to target it? We wondered whether all these different genes may be mediated by some shared downstream signaling that we can discover and target instead.

Junyue Cao, head of the Laboratory of Single-Cell Genomics and Population Dynamics at The Rockefeller University

Application in Melanoma Drug Resistance

To demonstrate the platform’s utility, the research team used melanoma drug resistance as a proof-of-concept. Their findings indicated that diverse genetic changes can push cells into the same harmful state of drug resistance.

By identifying the regulatory nodes common to these variations, the researchers showed that these shared points of control could lead to the development of combination therapies. Such therapies would be capable of targeting the disease across its many different genetic causes rather than treating each mutation individually.

Future Research and Scope

The study, titled Mapping convergent regulators of melanoma drug resistance by PerturbFate, was published in the journal Nature. The researchers noted that while the current proof-of-concept focused on cancer, the implications of the tool extend to other complex conditions.

Following the results in cultured cells, the team plans to transition the PerturbFate approach into living models. These future studies will focus on investigating the mechanisms of aging and Alzheimer’s disease to see if similar regulatory nodes can be identified and targeted in those contexts.